Mark L. Tykocinski, MD
Executive Vice President, Academic Affairs
Provost, Thomas Jefferson University
Dean, Sidney Kimmel Medical College
Before joining Jefferson in 2008, Tykocinski was professor and chair of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania for a decade. Under his leadership, it emerged as the #1 NIH-funded department of its kind in the country. This department also featured prominent postgraduate training programs in clinical laboratory diagnostics and transfusion medicine, as well as high-profile commercialization of biomedical discovery. Notably, lab-on-a-chip microfluidic and CAR-T cancer immunotherapy technologies were developed in the department and launched towards commercialization under his purview there.
Tykocinski’s research contributions have been in the fields of molecular and cellular immunology, cell surface engineering, and biologics innovation. He has pioneered new categories of fusion protein pharmaceuticals, with applications to cancer and autoimmune diseases. Tykocinski serves as scientific advisory board chair for KAHR-Medical, the Israeli biotech company he founded in 2007 for fusion protein pharmaceuticals. Tykocinski’s scientific contributions also extend to the development of novel cell therapy strategies and the engineering of a novel class of mammalian gene expression vectors now distributed worldwide. He holds a series of research patents in the fields of molecular and cellular immunology, and is a Fellow of the National Academy of Inventors.